Table 4 Development of PRO data submissions for rare diseases over time
Items | 2018 | Â | 2017 | Â | 2016 | Â | 2015 | Â | 2014 | Â | 2013 | Â | 2012 | Â | 2011 | Â |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assessment processes | 10 | Â | 16 | Â | 17 | Â | 15 | Â | 13 | Â | 3 | Â | 5 | Â | 2 | Â |
Clinical PROs | 4 | 40% | 12 | 75% | 11 | 65% | 6 | 40% | 4 | 31% | 0 | 0% | 0 | 0% | 0 | 0% |
HRQoL | 6 | 60% | 13 | 81% | 13 | 76% | 11 | 73% | 10 | 77% | 2 | 67% | 4 | 80% | 2 | 100% |
Preferences | 1 | 10% | 1 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
Satisfaction | 0 | 0% | 0 | 0% | 1 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |